Tutti gli studi
ReclutamentoFASE2INTERVENTISTICO

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

Pulmonary sarcoidosis is an inflammatory condition that causes tiny lumps of swollen tissue to develop in the lungs, leading to symptoms like coughing and shortness of breath. This clinical trial is studying an experimental medicine called OATD-01 to find out if it is safe, well-tolerated, and effective at calming this inflammation. Adults with active lung sarcoidosis can join. Participants are randomly put into two groups: one group takes OATD-01 daily, and the other takes a dummy pill called a placebo. The treatment period lasts for 12 weeks. Neither the participants nor the research team will know who receives which pill, ensuring the test results are reliable. Doctors will use specialised imaging scans and regular health checks to see how well the lungs respond. By participating, patients help scientists learn whether OATD-01 could become a valuable future treatment option for this condition.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE2
Sponsor
Molecure S.A.
Obiettivo di iscrizione
96
Inizio
21 Mar 2024
Completamento stimato
01 Set 2027

Di cosa tratta questo studio?

Sarcoidosis is a condition where the body's immune system overreacts, forming small clusters of inflamed cells called granulomas. While these can appear anywhere, they most commonly affect the lungs (pulmonary sarcoidosis). People with active sarcoidosis often struggle with a persistent dry cough, chest tightness, fatigue, and breathlessness. Current treatments often rely on steroids or strong medicines that suppress the immune system, but these can cause difficult long-term side effects.

This clinical trial is evaluating a new experimental drug named OATD-01. Scientists hope OATD-01 can target the inflammatory process directly and reduce swelling in the lungs without causing some of the side effects linked to older medicines. Because this is a Phase 2 trial, its primary purpose is to check how well the drug works, identify an effective dose, and ensure it is safe to take.

During the trial, doctors will use advanced imaging known as a PET/CT scan to take clear pictures of the lungs. This allows the medical team to see active inflammation before treatment begins and measure whether the study drug helps to settle it down over time.

Taking part in this study helps researchers gather crucial evidence about how the body handles OATD-01. Even if the medicine is not suitable for everyone, the findings from this trial could lead to better, more targeted treatment options for people living with sarcoidosis in the future.

Punti chiave

  • The trial tests a new medicine called OATD-01 for active sarcoidosis in the lungs.
  • Treatment lasts for 12 weeks, comparing OATD-01 against a dummy pill (placebo).
  • You have a 50% chance of receiving OATD-01 and a 50% chance of receiving the placebo.
  • Specialised PET/CT scans are used to track inflammation before and after treatment.
  • Participation is entirely voluntary and you can leave the study at any point.

Chi può essere idoneo?

This trial is open to men and women aged 18 and older who have an active, confirmed diagnosis of pulmonary sarcoidosis and are experiencing symptoms. To qualify, a PET/CT scan must show clear signs of active inflammation in the lung tissue. You may be able to take part whether you have never received treatment before, or have had treatments in the past that have now stopped.

To keep results clear and ensure patient safety, your current medications matter. You cannot join if you currently need urgent, immediate treatment for your sarcoidosis. If you previously took steroid tablets, you must have stopped them at least three months before joining. If you took stronger immune-suppressing drugs or biologic therapies, you must have stopped them at least four months ago.

You will not be able to participate if your sarcoidosis affects your heart or your brain and nervous system. You are also excluded if you have other significant lung conditions, such as asthma, COPD, or tuberculosis, or if you have serious heart problems, poorly controlled diabetes, or severe kidney or liver disease.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Are you aged 18 or over?
  2. Have you been diagnosed with active sarcoidosis in your lungs?
  3. Are you currently experiencing symptoms like a cough or shortness of breath?
  4. Have you been off steroid tablets for at least 3 months and off immune-suppressing drugs for at least 4 months?
  5. Are your heart, nervous system, and other organs free from active sarcoidosis?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you decide to take part, your involvement will last several months, including a 12-week treatment period. Before starting, you will attend screening visits to make sure the trial is safe for you. These visits will include blood tests, heart checks (such as an ECG), breathing tests, and a specialised PET/CT scan to look closely at your lungs. Once enrolled, you will be randomly assigned to take either OATD-01 or a matching placebo pill once daily for 12 weeks. You will have regular appointments at the study clinic so the medical team can monitor your health, check for any side effects, and see how your lungs are responding. After finishing the 12 weeks of treatment, you will have follow-up checks to ensure you remain well.

Rischi e benefici potenziali

You might not receive any direct medical benefit from taking part, especially if you are assigned to the placebo group, although your lung health will be monitored very closely by specialist doctors. There is also a risk of side effects from OATD-01, some of which may not yet be known, as well as minor discomfort from routine blood tests and exposure to low levels of radiation from PET/CT scans. Taking part is completely voluntary. You are free to leave the study at any time, for any reason, and doing so will not affect your normal medical care or your relationship with your healthcare team.

Locations (28)

  • Molecure Investigative Site
    Codice postale verificato
    Birmingham, Stati Uniti· Ritirato
  • Molecure Investigative Site
    Codice postale verificato
    Kansas City, Stati Uniti· Ritirato
  • Molecure Investigative Site
    Codice postale verificato
    Baltimora, Stati Uniti· Reclutamento
  • Molecure Investigative Site
    Codice postale verificato
    Rochester, Stati Uniti· Ritirato
  • Molecure Investigative Site
    Codice postale verificato
    Cleveland, Stati Uniti· Reclutamento
  • Molecure Investigative Site
    Codice postale verificato
    Philadelphia, Stati Uniti· Reclutamento
  • Molecure Investigative Site
    Codice postale verificato
    Charleston, United States· Reclutamento
  • Molecure Investigative Site
    Codice postale verificato
    Vejle, Denmark· Ritirato
  • Molecure Investigative Site
    Codice postale verificato
    Bobigny, France· Ritirato
  • Molecure Investigative Site
    Codice postale verificato
    Montpellier, Francia· Reclutamento
  • Molecure Investigative Site
    Codice postale verificato
    Parigi, Francia· Reclutamento
  • Molecure Investigative Site
    Codice postale verificato
    Parigi, Francia· Reclutamento

Domande comuni

What is a placebo and why is it used?

A placebo looks just like the real medicine but contains no active ingredients. Comparing OATD-01 against a placebo helps researchers prove whether any improvements or side effects are truly caused by the study drug.

Will I know if I am taking OATD-01 or the placebo?

No. This is a double-blind trial, meaning neither you nor your study doctor will know which treatment you are receiving until the study is finished, ensuring completely unbiased results.

What happens if my symptoms get worse during the study?

Your safety is always the top priority. If your breathing or sarcoidosis symptoms worsen, the trial doctors can pause or stop your study treatment and provide standard medical care immediately.

Do I have to pay to take part in this clinical trial?

No. All study medications, scans, and clinic visits are provided free of charge, and trial organisers often help cover reasonable travel expenses to and from the clinic.

Can I carry on seeing my regular GP or specialist?

Yes. You should continue to see your usual doctors. With your permission, the research team will keep your GP informed about your participation in the study.

Come saperne di più

Molecure SA

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Efficacy and Safety Study of OATD-01 in Patients With Active…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.